We have developed an inexpensive CRC diagnostic pipeline, which is capable of detecting both “typical” and “atypical” mutations in KRAS, NRAS and BRAF genes, even in samples with a low proportion of tumor cells, includes HER2 and MSI testing, and is characterized by low cost. This evidence concerns the gene KRAS and colorectal carcinoma.